Skip to search formSkip to main contentSkip to account menu

KE 758

Known as: KE-758 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Phenylbutyrates

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
KE-758, an active metabolite of the new anti-rheumatic drug KE-298, suppresses production of tumor necrosis factor-alpha and interleukin-1 beta in THP-1, a human monocyte cell line.
KE-758, an active metabolite of KE-298, is a novel sulfhydryl antirheumatic drug. We analyzed the effect of KE-758 on tumor… 
2002
2002
Effects of a new anti-rheumatic drug KE-298 and its active metabolite: KE-758 on secretion of thioredoxin and on the level of intracellular glutathione in human monocytes and T cells.
2001
2001
KE-298 and its active metabolite KE-758 suppress nitric oxide production by murine macrophage cells and peritoneal cells from rats with adjuvant induced arthritis.
OBJECTIVE To analyze the effects of KE-298 and KE-758 on lipopolysaccharide (LPS) induced nitric oxide (NO) production by the… 
2001
2001
Effects of KE-758; an active metabolite of the new anti-rheumatic drug KE-298, D-penicillamine, bucillamine and auranofin on the proliferation of murine lymphocytes, and the production of nitric…
1996
1996
Pharmacological profile of KE-758, the main metabolite of the antirheumatic agent KE-298.
KE-298(2-acetylthiomethyl-4-(4-methylphenyl)-4-oxobutanoic acid) is a newly developed antirheumatic drug which suppresses the… 
1993
1993
慢性関節リウマチ滑膜細胞のIL-6産生に対するKE-298, KE-758の作用
Rheumatoid synovial tissue produces excessive amounts of interleukin-6 (IL-6), which contributes to the immunopathogenesis of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)